Answers are grounded in this paper and cite their sources.
The second edition of The Macrophage comes at a time of resurgence of interest in innate immunity. The innate immune system depends upon a range of effector cells with genetically determined receptors recognising conserved molecular structures expressed by a wide variety of potential invading organisms, allowing it to distinguish between self and non-self. It thus differs from the adaptive immune system comprising B and T lymphocytes, in that it does not rely upon clonal selection of effector cells with unique antigen-specific receptors provided by rearrangement of multiple gene segments. This means that the innate system is capable of relatively rapid reactions, limited only by the time taken for cytokine cascades to take effect. Foremost among the cell types involved in the innate immune response are macrophages. Macrophages have a range of important functions in relation to inflammatory responses against foreign organisms, including phagocytosis of smaller cells such as bacteria, direct or antibody-directed killing of these and other organisms, and interaction with the adaptive immune system particularly in the area of antigen processing. With regard to cancer, macrophages form a significant proportion of the total cell population in the vast majority of tumour tissues and there is abundant evidence that under some conditions, they are capable of cytotoxic or cytostatic activity against malignant cells. However, there is a down side to all of this. Macrophage activity can also be destructive to the host, as, for example, its involvement in the development of atheromatous plaques and rheumatoid arthritis, and in cancer macrophages very often promote the survival and spread of tumour cells rather than inhibit them, depending on the local cellular and cytokine environment. This ambivalence was amply portrayed in the first edition of The Macrophage and is an unchanging consequence of the complex biology of macrophages. The complexity of tumour biology and the heterogeneity of tumours in general only serve to compound the problem for oncologists.
No takes yet. Share an insight, caveat, or question.
M. J. Embleton (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: